Compare Royal Caribbean Cruises Ltd (RCL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Zoetis Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $286.01 (market cap $76.75B), while Zoetis Inc trades at $74.04 (market cap $31.59B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| RCL | ZTS | |
|---|---|---|
Market Cap | $76.75B | $31.59B |
Sector | Consumer Cyclical | Health |
52-Week High | $365.84 | $156.76 |
52-Week Low | $246.71 | $71.91 |
Enterprise Value | $98.03B | $38.89B |
Dividend Yield | 1.75% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $287.90, near its 52-week high, with a modest 0.33% daily gain. The stock shows strong fundamental momentum, with revenue growing from $8.8B in 2022 to $17.9B in 2025 and net income surging to $4.3B. However, technical indicators signal a bearish trend, with moving averages and oscillators pointing to near-term pressure. Recent news highlights earnings anticipation and board appointments, while analyst consensus remains bullish with a $328 price target.
The outlook for RCL is positive based on robust earnings growth and expanding profit margins, but risks include high debt levels and potential economic sensitivity. Investor sentiment is mixed, with technical weakness offset by strong fundamentals. The stock presents a long-term opportunity if it can maintain operational execution amid competitive and macroeconomic challenges.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
